134 related articles for article (PubMed ID: 10210387)
1. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis.
Nam RK; Fleshner N; Rakovitch E; Klotz L; Trachtenberg J; Choo R; Morton G; Danjoux C
J Urol; 1999 May; 161(5):1521-4. PubMed ID: 10210387
[TBL] [Abstract][Full Text] [Related]
2. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent.
Lippert MC; McClain R; Boyd JC; Theodorescu D
Cancer; 1999 Dec; 86(12):2642-8. PubMed ID: 10594859
[TBL] [Abstract][Full Text] [Related]
3. Attitudes and use of alternative therapies in UK prostate cancer patients-isn't it time we were in the know?
Cheetham PJ; Le Monnier KJ; Brewster SF
Prostate Cancer Prostatic Dis; 2001; 4(4):235-241. PubMed ID: 12497025
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of prostate specific antigen testing for prostate cancer in elderly men.
Dyche DJ; Ness J; West M; Allareddy V; Konety BR
J Urol; 2006 Jun; 175(6):2078-82. PubMed ID: 16697807
[TBL] [Abstract][Full Text] [Related]
5. Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer.
Diefenbach MA; Hamrick N; Uzzo R; Pollack A; Horwitz E; Greenberg R; Engstrom PF
J Urol; 2003 Jul; 170(1):166-9. PubMed ID: 12796672
[TBL] [Abstract][Full Text] [Related]
6. The use of complementary therapy by men with prostate cancer in the UK.
Wilkinson S; Farrelly S; Low J; Chakraborty A; Williams R; Wilkinson S
Eur J Cancer Care (Engl); 2008 Sep; 17(5):492-9. PubMed ID: 18637112
[TBL] [Abstract][Full Text] [Related]
7. Patterns of local failure following prostate brachytherapy.
Stone NN; Stock RG; White I; Unger P
J Urol; 2007 May; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
[TBL] [Abstract][Full Text] [Related]
8. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer.
Peters CA; Stock RG; Blacksburg SR; Stone NN
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):24-9. PubMed ID: 18692325
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and patterns of self-initiated nutritional supplementation in men at high risk of prostate cancer.
Uzzo RG; Brown JG; Horwitz EM; Hanlon A; Mazzoni S; Konski A; Greenberg RE; Pollack A; Kolenko V; Watkins-Bruner D
BJU Int; 2004 May; 93(7):955-60. PubMed ID: 15142142
[TBL] [Abstract][Full Text] [Related]
10. A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer.
Eng J; Ramsum D; Verhoef M; Guns E; Davison J; Gallagher R
Integr Cancer Ther; 2003 Sep; 2(3):212-6. PubMed ID: 15035882
[TBL] [Abstract][Full Text] [Related]
11. Understanding the motivation for conventional and complementary/alternative medicine use among men with prostate cancer.
Singh H; Maskarinec G; Shumay DM
Integr Cancer Ther; 2005 Jun; 4(2):187-94. PubMed ID: 15911931
[TBL] [Abstract][Full Text] [Related]
12. Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study.
Beebe-Dimmer JL; Wood DP; Gruber SB; Douglas JA; Bonner JD; Mohai C; Zuhlke KA; Shepherd C; Cooney KA
Urology; 2004 Feb; 63(2):282-7. PubMed ID: 14972472
[TBL] [Abstract][Full Text] [Related]
13. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of the use of alternative therapies by men with localized prostate cancer.
Steginga SK; Occhipinti S; Gardiner RA; Yaxley J; Heathcote P
Patient Educ Couns; 2004 Oct; 55(1):70-7. PubMed ID: 15476992
[TBL] [Abstract][Full Text] [Related]
16. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support.
Balderson N; Towell T
Br J Health Psychol; 2003 May; 8(Pt 2):125-34. PubMed ID: 12804328
[TBL] [Abstract][Full Text] [Related]
18. An analysis of men with clinically localized prostate cancer who deferred definitive therapy.
Patel MI; DeConcini DT; Lopez-Corona E; Ohori M; Wheeler T; Scardino PT
J Urol; 2004 Apr; 171(4):1520-4. PubMed ID: 15017211
[TBL] [Abstract][Full Text] [Related]
19. Differences between urologists in the United States and Canada in the approach to prostate cancer.
Fleshner N; Rakovitch E; Klotz L
J Urol; 2000 May; 163(5):1461-6. PubMed ID: 10751858
[TBL] [Abstract][Full Text] [Related]
20. Use of complementary therapies among breast and prostate cancer patients during treatment: a multisite study.
Hann DM; Baker F; Roberts CS; Witt C; McDonald J; Livingston M; Ruiterman J; Ampela R; Crammer C; Kaw O
Integr Cancer Ther; 2005 Dec; 4(4):294-300. PubMed ID: 16282506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
